Dr. Christopher W. Ryan, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of Ny Upstate Medical University (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 121
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: State University of Ny Upstate Medical University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OR license MD24250
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 121
- Services billed
- 466
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 149 | 70 |
| Established patient office or other outpatient visit, 40-54 minutes | 77 | 44 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Portland, OR | 23 |
| Levothyroxine Sodium Other prescribers in Portland, OR | 20 |
| Prochlorperazine Maleate Other prescribers in Portland, OR | 20 |
| Prednisone Other prescribers in Portland, OR | 18 |
| Abiraterone Acetate | 12 |
| Nubeqa (darolutamide) | 12 |
| Cabometyx (cabozantinib s-malate) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 5 payments worth $576 in total to this clinician.
| Exelixis Inc. | $175 |
|---|---|
| Pfizer Inc. | $133 |
| Springworks Therapeutics, Inc. | $125 |
| Aveo Pharmaceuticals, Inc. | $117 |
| Merck Sharp & Dohme LLC | $25.70 |
| Food and Beverage | $550 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Feb 4, 2025 | Education KEYTRUDA · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $1,860,168 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembro…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Blad…
Merck Sharp & Dohme LLC - A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Ptc Therapeutics, Inc. · Terminated · NCT05269355 - Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals Inc. · Active, not recruiting · NCT03069469 - Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic …
Merck Sharp & Dohme LLC - A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Exelixis Inc. - Study name not reported
Organon Llc - An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.